Description
Composition- Teneligliptin 20 mg + Dapagliflozin 10 mg
Mode of Action- Combines incretin-based glucose regulation with renal glucose excretion for effective dual-pathway diabetes control.
USPs- Dual oral antidiabetic therapy; weight-neutral/weight benefit potential; low hypoglycemia risk.
Prescribing Specialties- Diabetologist, General Physician
